Lilly’s revenue soars 48%, driven by demand of its GLP-1s

HeadlineFlip summary

Eli Lilly's revenue increased by 48%, primarily due to strong demand for its GLP-1 drugs, Mounjaro and Zepbound, used for Type 2 diabetes and weight loss.